Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEUS vs MRI for Differentiation of Hepatic Lesions
NCT03652636Phase 4Completed
- Sponsor
- Indiana University
- Start
- Aug 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sulfur hexafluoride in focal nodular hyperplasia (FNH) and hepatic adenoma (HCA), sponsored by Indiana University. Primary endpoint: Accuracy of CEUS at Differentiating Focal Nodular Hyperplasia (FNH) From Hepatocellular Adenoma (HCA) at 1 day. Started Aug 2019; status: completed.
02
Drugs
sulfur hexafluoride
03
Conditions
focal nodular hyperplasia (FNH)hepatic adenoma (HCA)
Beyond the preview
Go deeper on NCT03652636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652636.